Inflammatory faCtors AfteR acUte Ischemic Stroke

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

ICARUS is an interventional single-centre hospital-based cohort study in patients admitted to the stroke unit with an acute ischemic stroke. The aims of the study are to i) define the characteristics and determinants of microglial activation after human stroke, and ii) assess the correlation of microglial activation with circulating inflammatory markers, structural brain changes on neuroimaging, and neurological outcomes. ICARUS involves serial TSPO-PET imaging along with serial MRI, immune cell profiling in blood, and both clinical and laboratory assessments in 36 patients with acute ischemic stroke caused by a cortical (N=18) or strictly subcortical (N=18) infarct. In a substudy, the investigators will include 10 independently recruited patients with acute ischemic stroke to assess MRI arterial spin labelling (ASL) sequences as a marker for perfusion measurement of the TSPO tracer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:

• Age ≥ 50 years

• Acute ischemic stroke (time frame: \<72 hours) as defined by an acute focal neurological deficit in combination with a corresponding infarct as documented by a diffusion weighted imaging (DWI)-positive lesion on magnetic resonance imaging (MRI); presence of an infarct involving the cortex or a strictly subcortical infarct

• Written informed consent prior to study participation

• Willingness to participate in study assessments including follow-up

Locations
Other Locations
Germany
Department of Nuclear Medicine
RECRUITING
Munich
Insitute for Stroke and Dementia Research
RECRUITING
Munich
Contact Information
Primary
Martin Dichgans, Prof.
martin.dichgans@med.uni-muenchen.de
+49 4400
Backup
Anna Kopczak, MD
anna.kopczak@med.uni-muenchen.de
+49 4400
Time Frame
Start Date: 2020-07-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 36
Treatments
Other: TSPO PET imaging
All study participants will receive \[18F\]-GE-180, i.e. TSPO PET imaging to assess microglia activation.
Related Therapeutic Areas
Sponsors
Collaborators: Universitätsklinikum Hamburg-Eppendorf, University Hospital Muenster
Leads: Martin Dichgans

This content was sourced from clinicaltrials.gov